XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties Transactions (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 08, 2020
Jan. 31, 2022
Oct. 31, 2020
Jul. 10, 2019
Jul. 19, 2017
Feb. 24, 2015
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2018
Dec. 01, 2021
Sep. 30, 2021
Sep. 07, 2021
Jul. 01, 2021
May 17, 2021
Jul. 01, 2020
Aug. 31, 2019
Feb. 27, 2019
Related Parties Transactions (Details) [Line Items]                                          
Advanced an aggregate amount             $ 547,525   $ 547,525   $ 49,110                    
Loan agreement, description                         The advances bear interest rate of 12% per annum.                
Outsanding loan amount                 531,384   33,520                    
Convertible loan             500,000   500,000                        
Principal amount             $ 1,000,000   $ 1,000,000                        
Conversion price (in Dollars per share)             $ 1   $ 1                 $ 2.25   $ 7  
Discount of stock price       70.00%         20.00%                        
Accrued interest             $ 40,878   $ 40,878   40,878                    
Consultant services agreement             $ 1,559   1,559   1,889                    
Loan agreement total amount   $ 507,000             $ 1,348,000                        
Interest rate   6.50%         6.50%   6.50%                        
Research and development cost             $ 532,782 $ 358,878 $ 892,186 $ 480,193                      
Maturity date         Jan. 19, 2018       Nov. 30, 2022                        
Due amount             116,640   $ 116,640   124,972                    
Outstanding principal and accrued interest             156,576   156,576   168,131                    
Interest expenses             $ 5,401 $ 5,694 10,714 10,992                      
BioFirst (Australia) [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Aggregate working capital                 $ 132,443   211,147                    
Due from rgene amounted                           $ 250,000   $ 67,873     $ 361,487    
Interest rate percentage                             6.50%            
Loan settled amount                                 $ 249,975        
Ownership percentage             6.50%   6.50%                        
Accrued interest                 $ 1,023,434                        
Research fee                     $ 491,816                    
LBG USA, Inc.[Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Ownership percentage                                         0.00%
AsiaGene [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Ownership percentage             0.00%   0.00%   0.00%                    
YuanGene [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Ownership percentage             0.00%   0.00%   0.00%                    
Jiangs [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Ownership percentage             0.00%   0.00%   1.00%                    
BioFirst [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Loan agreement, description                 the loan bears interest at 1% per month (or equivalent to 12% per annum)     The advances bear interest 1% per month (or equivalent to 12% per annum).                  
Accrued interest             $ 51,652   $ 51,652   $ 2,325                    
Aggregate working capital                     465,000                    
Balance of outstanding loans                 1,813,000   465,000                    
Research and development cost                 8,783 $ 1,110                      
AsiaGene [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Accrued interest             14,582   14,582   13,701                    
Aggregate working capital                 24,017   24,017                    
BHK Co Development Agreement [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Loan agreement, description           The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.                              
LBG USA, Inc.[Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Outstanding advance             675   675   675                    
BioLite Japan [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Loan agreement, description Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan’s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.                                        
Outstanding advance             150,000   150,000   150,000                    
Keypoint [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Balance of outstanding loans                 1,610   1,610                    
Loan agreement, description     the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.                                    
YuanGene [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Aggregate working capital                 9,205   9,205                    
Jiangs [Member]                                          
Related Parties Transactions (Details) [Line Items]                                          
Outstanding advance             $ 19,789   $ 19,789   $ 18,750